COMPARE · Data as of August 24, 2026
BHC vs GSK
Verdict: Side-by-side breakdown using the Bull Rankings model. BHC scored 71.3, GSK scored 49.1 — BHC leads.
Compare another set
Different reporting periods. BHC's fundamentals are as of June 2026, but GSK's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
BHC
Bausch Health Companies Inc.
71.3
$6.68 · $2.5B
fundamentals as of
Score gap
22.2
BHC leads
GSK
GSK plc
49.1
$51.78 · $103.7B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthBHC+10.1%
- Highest qualityGSK85 / 100
- Largest discount to fair valueBHC-86%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
BHC
stronger →← stronger
GSK
63
Qualityreturns · margins · balance sheet
85
64
Growthrevenue & earnings expansion
65
91
Valuevaluation vs sector peers
25
GSK is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
BHC
GSK
$1.4bC+
FCF
$7.3bB+
+10.1%B
Rev
+4.1%C+
—
D/E
1.06C
0.2xA
P/S
—
0.01A
PEG
104.84D
—
P/E
16.4xA-
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BHC
GSK
86% below
Price vs fair valuelower is cheaper
14% below
decline
Growth the price implies10-yr FCF · lower = less priced in
~2%/yr
+677%
1-yr DCF upside
+8%
+599%
5-yr DCF upside
+16%
+504%
10-yr DCF upside
+27%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BHC
GSK
Why this score
- Raising its dividend
- Durable high returns
- Foreign reporter (GBP)
The companies
BHCBausch Health Companies Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $2.5b. 17% off the 52-week high of $8.00. Revenue growing +10%, comfortably above the S&P median. PEG 0.01 — paying under fair value for the growth rate. 5 sell-side analysts publish a mean 1-yr target of $7.50 (implying +12% upside).
Moat
ROE 62% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -10.1%) — path to GAAP profitability is the core thesis risk. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
GSKGSK plc
Why now
Drug Manufacturers - General · market cap $103.7b. 16% off the 52-week high of $61.70. 8 sell-side analysts rate this a Hold with a mean 1-yr target of $58.08 (implying +12% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 39% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 111% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BHC and GSK diverge
On the headline score the gap is 22.2 points in favor of BHC. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueBHC 90.6 · GSK 24.9BHC +65.7
- QualityBHC 62.9 · GSK 85.3GSK +22.4
- GrowthBHC 63.7 · GSK 65.0level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.